Groundbreaking bowel cancer trial follow-up shows zero relapses
21 April 2026
A CTC-led clinical trial has found that patients with a specific type of bowel cancer remained cancer-free nearly three years after receiving immunotherapy before surgery.

The NEOPRISM-CRC trial tested a short course of the immunotherapy drug pembrolizumab in patients with stage 2 or 3 bowel cancer with a particular genetic profile. Researchers reported zero relapses after 33 months of follow-up. Given standard treatment, around one in four patients would normally see their cancer return.

Dr Kai-Keen Shiu, Chief Investigator of the trial from UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, said: “Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers.”

The full story can be read over at UCL News.

Image credit: Mikael Häggström
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
149 Tottenham Court Road
London
W1T 7NF

View map
Email:
ctc.enquiries@ucl.ac.uk

Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)

Postal Address:
Cancer Research UK & UCL Cancer Trials Centre
University College London
20 Bedford Way
London WC1H 0AL
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2026 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us